cabotegravir injectable
Selected indexed studies
- Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis. (Drugs, 2022) [PMID:36255686]
- Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis. (Ann Pharmacother, 2023) [PMID:35778802]
- Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis. (Am J Health Syst Pharm, 2022) [PMID:35894204]
_Worker-drafted node — pending editorial review._
Connections
cabotegravir injectable is a side effect of
Sources
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. (2023) pubmed
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. (2021) pubmed
- Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention? (2023) pubmed
- Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. (2022) pubmed
- Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis. (2022) pubmed
- Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis. (2022) pubmed
- Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis. (2023) pubmed
- Long-acting injectable cabotegravir for the prevention of HIV infection. (2020) pubmed
- Long-acting injectable cabotegravir and rilpivirine in observational cohort studies: A systematic review on virological failure, resistance and re-suppression outcomes in virally suppressed individuals living with HIV. (2025) pubmed
- PMID:36417549 (2022) pubmed